Gavin: Well, we’ve got a very rich preclinical pipeline. I can’t really discuss that. We have a number of molecules that are in clinical development at this point.

I mentioned the BTK inhibitor. We also have a TYK2 compound that’s coming forward. We also have programs in S1P1 [in Phase I for an undisclosed indication] and IP-10 [BMS-936557 in Phase II for ulcerative colitis and Crohn's disease] that are ongoing.

So we’ve got a number of different molecules, and we’re really looking at how we can affect those different components of the immune system, and really think about the immune system as something, not necessarily to inhibit, but to modulate. You want to be able to adjust how it responds, depending on what disease state you’re talking about.

BMS Q&A: Hunting For Biomarkers To Improve Treatment Of Autoimmune Diseases

More from Immunological

More from Therapeutic Category